-DOCSTART- -X- O
We -X- _ O
assessed -X- _ O
the -X- _ O
cost-effectiveness -X- _ O
and -X- _ O
cost-utility -X- _ O
of -X- _ O
treating -X- _ O
influenza -X- _ B-Patient
with -X- _ O
neuraminidase -X- _ B-Intervention
inhibitors -X- _ I-Intervention
( -X- _ I-Intervention
oseltamivir -X- _ I-Intervention
and -X- _ I-Intervention
zanamivir -X- _ I-Intervention
) -X- _ I-Intervention
from -X- _ O
a -X- _ O
health -X- _ O
care -X- _ O
payer’s -X- _ O
and -X- _ O
societal -X- _ O
perspective -X- _ O
in -X- _ O
the -X- _ O
United -X- _ O
Kingdom. -X- _ O
A -X- _ O
simulation -X- _ O
model -X- _ O
was -X- _ O
developed -X- _ O
to -X- _ O
predict -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
due -X- _ O
to -X- _ O
influenza -X- _ O
and -X- _ O
its -X- _ O
specified -X- _ O
complications -X- _ O
, -X- _ O
comparing -X- _ O
neuraminidase -X- _ B-Intervention
inhibitors -X- _ I-Intervention
with -X- _ O
usual -X- _ B-Comparison
care -X- _ I-Comparison
in -X- _ O
an -X- _ O
otherwise -X- _ O
healthy -X- _ O
adult -X- _ O
population. -X- _ O
Robustness -X- _ O
of -X- _ O
the -X- _ O
results -X- _ O
was -X- _ O
tested -X- _ O
by -X- _ O
one-way -X- _ O
and -X- _ O
multiway -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
probabilistic -X- _ O
sensitivity -X- _ O
analyses. -X- _ O
Treatment -X- _ B-Outcome
with -X- _ I-Outcome
either -X- _ I-Outcome
neuraminidase -X- _ I-Outcome
inhibitor -X- _ I-Outcome
results -X- _ I-Outcome
in -X- _ I-Outcome
reduced -X- _ I-Outcome
morbidity -X- _ I-Outcome
and -X- _ I-Outcome
faster -X- _ I-Outcome
return -X- _ I-Outcome
to -X- _ I-Outcome
normal -X- _ I-Outcome
activities. -X- _ I-Outcome
However -X- _ O
, -X- _ O
oseltamivir -X- _ B-Outcome
dominates -X- _ I-Outcome
zanamivir -X- _ I-Outcome
in -X- _ I-Outcome
cost-utility -X- _ I-Outcome
analysis -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
its -X- _ I-Outcome
lower -X- _ I-Outcome
costs. -X- _ I-Outcome
Comparing -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
with -X- _ I-Outcome
usual -X- _ I-Outcome
care -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
costs -X- _ I-Outcome
are -X- _ I-Outcome
£14.36 -X- _ I-Outcome
per -X- _ I-Outcome
day -X- _ I-Outcome
of -X- _ I-Outcome
normal -X- _ I-Outcome
activity -X- _ I-Outcome
gained -X- _ I-Outcome
and -X- _ I-Outcome
£5,600 -X- _ I-Outcome
per -X- _ I-Outcome
quality-adjusted -X- _ I-Outcome
life-year -X- _ I-Outcome
gained -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
healthcare -X- _ I-Outcome
payer -X- _ I-Outcome
perspective. -X- _ I-Outcome
Oseltamivir -X- _ O
dominates -X- _ O
usual -X- _ O
care -X- _ O
from -X- _ O
the -X- _ O
societal -X- _ O
perspective. -X- _ O
Treatment -X- _ O
with -X- _ O
oseltamivir -X- _ O
is -X- _ O
a -X- _ O
cost-effective -X- _ O
strategy -X- _ O
for -X- _ O
otherwise -X- _ O
healthy -X- _ O
adults -X- _ O
in -X- _ O
the -X- _ O
UK -X- _ O
from -X- _ O
both -X- _ O
the -X- _ O
healthcare -X- _ O
payer -X- _ O
and -X- _ O
societal -X- _ O
perspective -X- _ O
. -X- _ O

